MyWiki

AZ

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Pfizer, AstraZeneca vaccine antibodies may reduce by 50% after 2-3 months: Lancet study
COVID-19 Vaccine AstraZeneca UK - GOV.UK

(有AZ不同劑別/不同週期接種第二劑的反應)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
How long will vaccines continue to protect against COVID?

編輯 - 頁面歷史 - 列印 - 群組更新記錄 - 搜尋

Page last modified on 2021 年 08 月 29 日，M 上午